Research programme: leishmaniasis DNA vaccine - Mologen/LEISHDNAVAX Consortium

Drug Profile

Research programme: leishmaniasis DNA vaccine - Mologen/LEISHDNAVAX Consortium

Alternative Names: MGN 1331; MIDGE-based leishmaniasis DNA vaccine - Mologen/LEISHDNAVAX Consortium

Latest Information Update: 29 Jun 2016

Price : $50

At a glance

  • Originator LEISHDNAVAX Consortium; Mologen
  • Class DNA vaccines; Leishmaniasis vaccines; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Leishmaniasis

Most Recent Events

  • 09 Jun 2016 Discontinued - Preclinical for Leishmaniasis in Europe (Parenteral)
  • 26 Jun 2012 Mologen completes preclinical trials of MGN 1331 in Leishmaniasis
  • 12 Aug 2010 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top